Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-04
2007-12-04
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S217050, C514S217070, C514S234800, C514S249000, C540S546000, C540S593000, C540S599000, C544S119000, C544S353000
Reexamination Certificate
active
10910925
ABSTRACT:
Amidophenyl-sulfonylamino-quinoxaline compounds of formula (I)are CCK2 modulators useful in the treatment of CCK2 mediated diseases.
REFERENCES:
patent: 5847125 (1998-12-01), McDonald
patent: 6239131 (2001-05-01), Shinozaki et al.
patent: 2004/0235849 (2004-11-01), Beyreuther et al.
patent: 2006/0069286 (2006-03-01), Allison et al.
patent: WO 95/04720 (1995-02-01), None
patent: WO 02087568 (2002-11-01), None
patent: WO 02088073 (2002-11-01), None
patent: WO 02100825 (2002-12-01), None
patent: WO 04/13087 (2004-02-01), None
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Hawley's Condensed Chemical Dictionary, 13th ed., Richard J. Lewis, Sr., © 1997 by Van Nostrand Reinhold. p. 587.
Swift and Smith “Cholecystokinin Analog, JMV-180, Stimulates Growth of Pancreatic Cancer” Digestive Diseases and Sciences, vol. 39(5), pp. 1007-1013 (May 1994).
Malecka-Panas “The Role of Gastrin in Colorectal Carcinogenesis” International Review of Allergology & Clinical Immunology, vol. 6(4), pp. 151-156 (2000). ABSTRACT.
Konturek et al, “H. Pylori, Atrophic Gastritis, Cytokines, Gastrin, COX-2, PPAR Gamma and Impaired Apoptosis in Gastric Carcinogenesis” Medical Science Monitor, vol. 9(7), pp. SR53-SR66 (Jul. 2003). ABSTRACT.
Haigh et al, “Gastrin Induces Proliferation in Barrett's Metaplasia Through Activation of the CCK2 Receptor” Gastroenterology, vol. 124, pp. 615-625 (Mar. 2003).
Lehy et al, “Histomorphological Characteristics of Gastric Mucosa in Patients with Zollinger-Ellison Syndrome or Autoimmune Gastric Atrophy: Role of Gastrin and Atrophying Gastritis” Microscopy Research Tech., vol. 48(6), pp. 327-338 (Mar. 29, 2000). ABSTRACT.
Tonini et al, “Novel Therapeutic Strategies in Acid-Related Disorders,” Expert Opinion on Therapeutic Patents, vol. 13(5), pp. 639-649 (2003). ABSTRACT.
Lewin et al, “Primary Gastrin Cell Hyperplasia. Report of Five Cases and a Review of the Literature” American Journal of Surgical Pathology, vol. 8(11), pp. 821-832 (Nov. 1984).
Romanenko et al, “Condensed and Bonded Quinoxalines IV. New Path to Arylamides (1,2-Dihydro—2-hydroxyquinoxalyl-3) Acetic Acid” Khimiya Geterotsiklicheskikh Soyedineniy, vol. 2, pp. 264-266 (1973) ENGLISH TRANSLATION.
Cameroni et al, “Structure of Various Nitro Derivatives of 7-Chloro-1,2,4-benzothiadiazine-1,1-dioxide” Gazzetta Chimica Italiana, vol. 96(4), pp. 349-358 (1966). As Abstracted by CAS Online (STN).
Black, J.W. and S.B. Kalindjian. Gastrin Agonists and Antagonists. Pharmacol. Toxicol. 2002, 91:275-281.
de Tullio, P. et al. Therapeutic and Chemical Developments of Cholecystokinin Receptor Ligands. Exp. Opin. Invest. Drugs 2000, 9(1):129-146.
Herranz, R. Cholecystokinin Antagonists: Pharmacological and Therapeutic Potential. Med. Res. Rev. 2003, 23(5):559-605.
McDonald, I.M. CCK2 Receptor Antagonists. Exp. Opin. Ther. Patents. 2001, 11(3):445-462.
Morton, M.F. et al. Pharmacological Comparison of the Alternatively Spliced Short and Long CCK2 Receptors. Br. J. Pharmacol. 2003, 140(1):218-224.
Revel, L. and F. Makovec. Update on Nonpeptide CCK-B Receptor Antagonists. Drugs Future. 1998, 23(7):751-766.
Tracy, H.J. and R.A. Gregory. Physiological Properties of a Series of Peptides Structurally Related to Gastrin 1. Nature (London) 1964, 204:935-938.
Varnavas, A. et al. Anthranilic Acid Based CCK1 Antagonists: The 2-Indole Moiety May Represent a “Needle” According to the Recent Homonymous Concept. Eur. J. Med. Chem. 2004, 39:85-97.
Varnavas, A. et al. Anthranilic Acid Derivatives: A New Class of Non-Peptide CCK1 Receptor Antagonists. Bioorg. Med. Chem. 2003, 11:741-751.
Varnavas, A. et al. Synthesis of N-Terminal Substituted Anthranilic Acid Dimer Derivatives for Evaluation on CCK Receptors. II Farmaco. 2001, 56:555-564.
PCT International Search Report, dated Dec. 14, 2004, for PCT Int'l. Appln. No. PCT/US2004/025153.
Varnavas, A. et al., “Synthesis of new anthranilic acid dimer derivatives and their evaluation on CCK receptors”, II Farmaco, Rome Italy, vol. 55, No. 5, 2000, pp. 369-375.
Allison Brett D.
Hack Michael D.
Phuong Victor K.
Rabinowitz Michael H.
Rosen Mark D.
Janssen Pharmaceutica N.V.
Tucker Zachary C
LandOfFree
Quinoxaline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoxaline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoxaline compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3875043